Sugi Predict

Sugi Predict / Compounds / SCHEMBL1193272

SCHEMBL1193272

SCHEMBL1193272

CCOC(=O)c1cnn(-c2nc3cc(NCCN4CCOCC4)c(Cl)cc3n2COCCOC)c1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ EGLN1 Q9GZT9 3/20 0.51
▸ KMT2A Q03164 4/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ RXFP1 Q9HBX9 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ PTGER4 P35408 1/20 0.38
▸ IGF1R P08069 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ LCK P06239 1/20 0.37
▸ CYP3A4 P08684 1/20 0.36
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1193339 0.90 EGLN1 (0.50) EGLN1KMT2AMEN1ALDH1A1MAPK1
SCHEMBL1193469 0.87 EGLN1 (0.45) EGLN1ALDH1A1KDM4EPTGER4
SCHEMBL1193636 0.84 EGLN1 (0.42) EGLN1ALDH1A1KDM4ESMN1; SMN2PTGER4
SCHEMBL1193440 0.83 EGLN1 (0.47) EGLN1ALDH1A1KDM4ESMN1; SMN2PTGER4
SCHEMBL1193437 0.82 EGLN1 (0.46) EGLN1ALDH1A1KDM4EPTGER4
SCHEMBL1192795 0.82 EGLN1 (0.39) EGLN1KMT2AMEN1ALDH1A1KDM4E
SCHEMBL1193365 0.81 EGLN1 (0.44) EGLN1KMT2AMEN1ALDH1A1KDM4E
SCHEMBL1192982 0.80 PTGER4 (0.36) EGLN1KMT2AMEN1PTGER4
SCHEMBL1193033 0.80 EGLN1 (0.38) EGLN1PTGER4
SCHEMBL1193020 0.78 PTGER4 (0.36) EGLN1ALDH1A1MAPK1PTGER4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11618744-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2023-04-04 — — US disclosed
US-20210078978-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-03-18 — — US disclosed
US-10851083-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2020-12-01 — — US disclosed
US-20180215732-A9 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-08-02 — — US disclosed
US-20180022733-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-01-25 — — US disclosed
US-20160168127-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2016-06-16 — — US disclosed
US-9073923-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-07-07 — — US disclosed
EP-2294066-B9 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2015-03-11 — — EP disclosed
US-8865713-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-10-21 — — US disclosed
US-20140256722-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-11 — — US disclosed
EP-2294066-B1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-08-13 — — EP disclosed
US-8759345-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 — — US disclosed
US-20140005193-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (US) 2014-01-02 — — US disclosed
US-20110046132-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2011-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11618744-B2 Benzoimidazoles as prolyl hydroxylase inhibitors P4HA1, PAH, EGLN3 EGLN1 8/4885KMT2A 1663/4885MEN1 4176/4885
US-20110046132-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 10/4885KMT2A 1901/4885MEN1 4038/4885
US-20180022733-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 8/4885KMT2A 1663/4885MEN1 4176/4885
US-20140005193-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 8/4885KMT2A 1663/4885MEN1 4176/4885
US-10851083-B2 Benzoimidazoles as prolyl hydroxylase inhibitors P4HA1, PAH, EGLN3 EGLN1 8/4885KMT2A 1663/4885MEN1 4176/4885
US-20180215732-A9 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 8/4885KMT2A 1663/4885MEN1 4176/4885
US-20140256722-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 8/4885KMT2A 1663/4885MEN1 4176/4885
US-20210078978-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 8/4885KMT2A 1663/4885MEN1 4176/4885
US-20160168127-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 8/4885KMT2A 1663/4885MEN1 4176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.